K. A. Kern

414 total citations
11 papers, 344 citations indexed

About

K. A. Kern is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, K. A. Kern has authored 11 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in K. A. Kern's work include Cancer Treatment and Pharmacology (9 papers), Advanced Breast Cancer Therapies (6 papers) and HER2/EGFR in Cancer Research (4 papers). K. A. Kern is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Advanced Breast Cancer Therapies (6 papers) and HER2/EGFR in Cancer Research (4 papers). K. A. Kern collaborates with scholars based in United States, Spain and United Kingdom. K. A. Kern's co-authors include Xin Huang, John Crown, Gilles Romieu, DA Yardley, Vanessa Tassell, N. Davidson, Véronique Dièras, Thomas Bachelot, Elżbieta Starosławska and M. Lichinitser and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Parenteral and Enteral Nutrition.

In The Last Decade

K. A. Kern

11 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. A. Kern United States 5 149 135 85 80 71 11 344
Naoyuki Komura Japan 6 331 2.2× 85 0.6× 56 0.7× 127 1.6× 22 0.3× 6 429
Chie Ogawa Japan 11 73 0.5× 181 1.3× 37 0.4× 161 2.0× 32 0.5× 20 482
Jürgen Böhm United States 11 115 0.8× 125 0.9× 10 0.1× 166 2.1× 110 1.5× 15 383
Chris Tucker United States 8 148 1.0× 57 0.4× 66 0.8× 41 0.5× 14 0.2× 10 395
M G Thomas United Kingdom 6 32 0.2× 128 0.9× 81 1.0× 104 1.3× 46 0.6× 7 421
Mehrane Mehramiz Iran 12 32 0.2× 64 0.5× 26 0.3× 106 1.3× 55 0.8× 26 289
Meili Ma China 10 43 0.3× 83 0.6× 11 0.1× 105 1.3× 87 1.2× 25 293
S Mikami Japan 10 107 0.7× 28 0.2× 62 0.7× 66 0.8× 12 0.2× 29 391
N.M. Forones Brazil 8 57 0.4× 107 0.8× 19 0.2× 61 0.8× 33 0.5× 18 278
M.–C. Boutron–Ruault France 7 36 0.2× 118 0.9× 106 1.2× 44 0.6× 41 0.6× 14 345

Countries citing papers authored by K. A. Kern

Since Specialization
Citations

This map shows the geographic impact of K. A. Kern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. A. Kern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. A. Kern more than expected).

Fields of papers citing papers by K. A. Kern

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. A. Kern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. A. Kern. The network helps show where K. A. Kern may publish in the future.

Co-authorship network of co-authors of K. A. Kern

This figure shows the co-authorship network connecting the top 25 collaborators of K. A. Kern. A scholar is included among the top collaborators of K. A. Kern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. A. Kern. K. A. Kern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Kern, K. A., et al.. (2011). Comparative PARP enzyme inhibition of PF-01367338, olaparib, and MK-4827.. Journal of Clinical Oncology. 29(15_suppl). e13552–e13552. 4 indexed citations
3.
Kern, K. A., M. Carpentieri, Mark R. Middleton, et al.. (2011). Absolute bioavailability of PF-01367338 tablets following oral administration in cancer patients.. Journal of Clinical Oncology. 29(15_suppl). e13615–e13615. 1 indexed citations
4.
Crown, John, Véronique Dièras, Elżbieta Starosławska, et al.. (2010). Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).. Journal of Clinical Oncology. 28(18_suppl). LBA1011–LBA1011. 56 indexed citations
5.
Bergh, Jonas, Alain Lortholary, Xin Huang, et al.. (2010). Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).. Journal of Clinical Oncology. 28(18_suppl). LBA1010–LBA1010. 36 indexed citations
6.
Curigliano, Giuseppe, Xavier Pivot, Javier Cortés, et al.. (2010). Abstract P6-12-02: A Randomized Phase II Study of Sunitinib vs. Standard of Care for Patients with Previously Treated Advanced Triple-Negative Breast Cancer. Cancer Research. 70(24_Supplement). P6–12. 7 indexed citations
7.
Bachelot, Thomas, Aňa Lluch, Catherine Prady, et al.. (2009). Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.. Cancer Research. 69(2_Supplement). 4115–4115. 3 indexed citations
8.
Blay, Jean‐Yves, Aňa Lluch, Catherine Prady, et al.. (2009). 5003 Phase II study of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: activity and safety results. European Journal of Cancer Supplements. 7(2). 260–261. 3 indexed citations
9.
Miller, Katelyn D., Susan M. Perkins, Benjamin Schneider, et al.. (2009). An Exploratory Study of the Biological Activity of Sunitinib as a Component of Neoadjuvant Therapy for Breast Cancer.. Cancer Research. 69(24_Supplement). 202–202. 2 indexed citations
10.
Chuang, Ellen, Alex Starr, Penny Gowland, et al.. (2007). 2107 POSTER Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer. European Journal of Cancer Supplements. 5(4). 216–216. 4 indexed citations
11.
Kern, K. A., et al.. (1988). Cancer cachexia. Journal of Parenteral and Enteral Nutrition. 12(3). 286–298. 225 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naoyuki Komura Breakdown of academic impact, for papers by Chie Ogawa Breakdown of academic impact, for papers by Jürgen Böhm Breakdown of academic impact, for papers by Chris Tucker Breakdown of academic impact, for papers by M G Thomas Breakdown of academic impact, for papers by Mehrane Mehramiz Breakdown of academic impact, for papers by Meili Ma Breakdown of academic impact, for papers by S Mikami Breakdown of academic impact, for papers by N.M. Forones Breakdown of academic impact, for papers by M.–C. Boutron–Ruault
Rankless by CCL
2026